The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable foresight and end-to-end visibility. MDaudit to acquire all outstanding shares of Streamline stock for $5.34 per share in cash, a premium of 138% to Streamline’s closing price on May 28, 2025. Boston, Mass. and Atlanta, Ga., May 29, 2025 (GLOBE NEWSWIRE) -- MDau ...

Owens & Minor (OMI) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Jackie Marcus - Senior Managing DirectorEdward A. Pesicka - President, CEO & DirectorJon Leon - EVP & CFOJohn Stansel - VP - Equity ResearchAhmed Muhammad - AssociateKevin Caliendo - Managing Director Conference Call Participants Luismario Higuera - AnalystEric Coldwell - Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conf ...

Owens & Minor (OMI) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investo ...

Waystar Holding (WAY) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Waystar First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your qu ...

Z Highlights 01 重塑医疗保险报销体系，减轻诊所与患者医保申请负担 在美国，医疗保险理赔流程极为复杂低效。医疗服务提供者为患者提供服务后，保险索赔并非即时到账，往往需要经历漫长且不透明的报销流程。统计显 示，医疗机构首次申请理赔的成功率通常只有 60%~80% ， 近 20%~40% 的应收款在初次提交时被拒付或拖延 。赔付周期可能长达数月，给机构现金流带 来巨大压力。 小型诊所因此常陷入资金周转困难，甚至面临破产风险 。 这些问题催生了 所谓的 " 收入周期管理 " （ Revenue Cycle Management, RCM ）行业 ：医疗机构将理赔事务外包给 RCM 公司，后者通过大量（往往是 数百甚至上千名）人工手动处理索赔，与保险公司周旋。然而传统 RCM 服务费用高昂，且这些人往往缺乏对计费标准和临床事务的细致理解。 在这样的背景下， Camber 公司应运而生。 Camber 公司是一家人工智能驱动的医疗保险理赔自动化平台， 成立于 2021 年，由 Christophe Ri 、 Nathan Lee 和 Celina Qi 共同创立。 公司愿景是重塑医疗保险报销体系 ，致力于 ...

Financial Data and Key Metrics Changes - The company completed its 2022 restatement and is on track to become current with its filing obligations [6][8] - For 2023, estimated GAAP revenue is projected to be between $620 million and $625 million, with recurring revenue making up approximately 80% of total revenue [23][24] - Adjusted EBITDA for 2023 is estimated to be between $139 million and $144 million, which is higher than previously estimated [24] - For 2024, GAAP revenue is estimated to be between $583 million and $588 million, with a recurring revenue percentage consistent with prior years [27] - Adjusted EBITDA for 2024 is estimated to be between $85 million and $90 million, below previous guidance [29][30] Business Line Data and Key Metrics Changes - Provider business revenue dipped by 1% year-over-year, while payer and life sciences revenue declined by 10% [27][28] - The company signed significant contracts in its provider business, including a multimillion-dollar deal with a large urology practice and a major wound care organization [13][14] - The payer business saw the onboarding of nearly 400 new sites in 2025, with care gap alerts provided to over 3,500 healthcare practices [14] Market Data and Key Metrics Changes - The company experienced unexpected revenue shortfalls in the payer and life sciences segments, particularly in Q4 of 2024 [26][68] - The life sciences segment saw softness in media revenue and real-world data sales, while the payer segment faced implementation delays [68] Company Strategy and Development Direction - The company aims to remediate material weaknesses and enhance internal controls while executing its growth strategy [15][36] - The focus is on expanding the core provider base and enhancing the value of offerings, including AI-enabled workflows [15][16] - The company is pursuing additional debt financing to ensure liquidity and support future growth [80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business model despite revenue shortfalls and emphasized the importance of operational improvements [12][36] - The outlook for 2025 anticipates flat revenue compared to 2024, with expectations of growth from new customers offset by customer attrition [32][58] - Management noted that the remediation efforts and regaining current filing status are expected to occur in 2026 [33][41] Other Important Information - The company incurred significant external audit and legal fees in 2023 and 2024, impacting cash flow [9][30] - The acquisition of Science.io and Koa Health is expected to impact EBITDA margins due to new costs associated with these businesses [101][102] Q&A Session Summary Question: Clarification on remediation efforts and filing status - Management clarified that remediation efforts can continue while regaining currency on filings, with both expected to occur in 2026 [38][40] Question: Net attrition in provider business - Higher net attrition was noted in the core provider business, particularly in revenue cycle management, but not driven by market consolidation [44][46] Question: Revenue visibility for FY 2025 - Management indicated that while revenue is expected to be flat, there are uncertainties due to customer attrition and the need for a rebound from the previous year's shortfall [60][63] Question: Trends in life sciences and pharma segment - Management noted softness in media revenue but observed a pickup in spending in Q1 2025, indicating potential recovery in the life sciences segment [89] Question: Impact of acquisitions on financials - The acquisition of Science.io is not expected to contribute revenue in 2024, but it is seen as a strategic investment in AI capabilities [97][100]

CareCloud (CCLD) Q4 2024 Earnings Call March 13, 2025 08:30 AM ET Company Participants Kristen Rothe - Corporate Counsel and Privacy OfficerStephen Snyder - Co- CEOHadi Chaudhry - CEO & PresidentNorman Roth - Interim CFO, Principal Accounting Officer & ControllerMahmud Haq - Founder & Executive ChairmanJeffrey Scott Cohen - Director of Research Conference Call Participants Michael Kim - Senior AnalystAllen Klee - MD & Senior Research Analyst Operator Greetings, and welcome to the CareCloud Fourth Quarter tw ...

Pediatrix Medical Group, Inc. (NYSE:MD) Q4 2024 Earnings Conference Call February 20, 2025 9:00 AM ET Company Participants Charles Lynch - Senior Vice President, Finance & Strategy Mark Ordan - Chief Executive Officer Kasandra Rossi - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants A.J. Rice - UBS Jack Levin - Jefferies Whit Mayo - Leerink Partners Benjamin Shaver - Deutsche Bank Operator Thank you for standing by. My name is Tammy, and I will be your conference op ...